PMV Pharmaceuticals PMVP 深 滬
等待開盤 10-28 09:30:00 美东时间
1.25
+0.120
+10.62%
華盛通- 最 高1.28
- 今 開1.17
- 成交量 37.47万股
- 最 低 1.155
- 昨 收 1.13
- 總市值 9439.13万
- 52周最高 1.91
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 1.02
- 委 比 -85.63%
- 總股本 7551.31万
- 歷史最高 63.22
- 量 比 1.22
- 振 幅 11.06%
- 歷史最低 0.81
- 每 手 1
- 風險率 0.15%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PMV Pharmaceuticals Appoints Matt Eckler, Ph.D., to Board of Directors
PMV Pharmaceuticals announced the appointment of Dr. Matt Eckler to its Board of Directors. With over two decades of experience in healthcare investing and scientific research, Dr. Eckler will contribute strategic insights as the company prepares to submit an NDA for rezatapopt in 2027. Rezatapopt, a first-in-class p53 reactivator, targets the Y220C mutation in ovarian cancer and has received FDA Fast Track and Orphan Drug Designations. Dr. Eckle...
10-05 12:00
PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
PMV Pharmaceuticals appoints Philip Herman as Chief Commercial Officer to lead commercial strategy and launch preparation for rezatapopt, a first-in-class p53 reactivator. The company plans to submit an NDA for accelerated approval of rezatapopt in platinum-resistant/refractory ovarian cancer patients in Q1 2027. Herman brings over 24 years of experience in oncology and rare disease therapies, previously leading launches at Repare Therapeutics an...
09-08 12:00
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals Inc. (NASDAQ:PMVP) on Monday shared interim data from its Phase 2 PYNNACLE trial for rezatapopt, an investigational treatment for ovarian cancer. Based on this data, the company announced its plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (F...
09-01 21:01
PMV Pharma prices $50M IPO at $1.21 per share
PMV Pharmaceuticals (PMVP) priced an oversubscribed public offering expected to raise about $50.8M in gross proceeds. The offering includes 22.055M shares of common stock and pre-funded warrants to pu...
09-01 16:47
PMV Pharmaceuticals shares are trading lower after the company announced the commencement of an underwritten public offering.
PMV Pharmaceuticals shares are trading lower after the company announced the commencement of an underwritten public offering.
09-01 04:21
PMV Pharma announces proposed public offering
PMV Pharmaceuticals (PMVP) said on Monday it launched an underwritten public offering of common stock and accompanying warrants. The company may also offer pre-funded warrants to certain investors in...
09-01 04:08
PMV Pharma Announces Proposed Public Offering of Securities
PMV Pharmaceuticals announced the commencement of an underwritten public offering of its common stock, warrants, and pre-funded warrants. TD Cowen is the sole book-running manager. The offering is subject to market conditions and SEC registration. The securities are being offered under a shelf registration statement on Form S-3 (Registration No. 333-283349). A preliminary prospectus supplement will be filed with the SEC. This press release does n...
08-31 20:02
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PMV Pharmaceuticals announced interim data from the Phase 2 PYNNACLE trial for rezatapopt in ovarian cancer patients with TP53 Y220C mutations. The trial showed a 46% overall response rate (ORR) with a median duration of response of 10.0 months. Rezatapopt demonstrated a favorable safety profile, with mostly Grade 1 and 2 treatment-related adverse events. The company received FDA feedback supporting its NDA submission strategy for accelerated app...
08-31 20:01
PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41) per share from the same period last year.
08-14 20:12
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PMV Pharmaceuticals reported the completion of enrollment for the Phase 2 monotherapy portion of the PYNNACLE clinical trial for platinum-resistant/refractory ovarian cancer patients. The company plans to submit an NDA for Rezatapopt in the first quarter of 2027. As of June 30, 2026, the company had $79.4 million in cash, cash equivalents, and marketable securities, providing a cash runway through the second quarter of 2027.
08-14 12:00
